PRNewsWire
12 Oct 2026, 18:43 UTC · 1h ago
Impact · against what's priced in
STERIS is expected to see a modest boost in its long-term organic growth profile by acquiring Xodus Medical, a double-digit growth business specializing in surgical consumables. The deal expands STERIS's operating room footprint and complements its core mission of infection prevention.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
STERIS (NYSE: STE) has entered into an agreement to acquire Xodus Medical.
Newpress release dated Oct 12, 2026
So whatThe addition of a double-digit growth business should be accretive to STE's organic growth rate starting in FY2027.
More positive than 67% of claims this week
The acquisition adds Xodus Medical's specialty surgical consumables portfolio to STERIS's existing offerings.
Continue reading
5 related stories
The acquisition of Xodus Medical adds a specialty surgical consumables portfolio that has demonstrated double-digit growth, which is expected to be accretive to STERIS's organic growth rate starting in FY2027.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Newpress release dated Oct 12, 2026
More positive than 54% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Acquiring a double-digit growth company that complements its portfolio and expands its surgical consumables offering.
More positive than 51% of ticker scores this week
Serving as the exclusive financial advisor for the acquisition.
More positive than 51% of ticker scores this week
Serving as the exclusive financial advisor for Xodus Medical.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
4h ago
+2.1%
Price agrees with the score
$218.88 vs $214.40 close before publication (Oct 9) · not market-adjusted
STE chart →
